Fmr LLC Increases Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

FMR LLC increased its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 0.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,439,281 shares of the company's stock after acquiring an additional 36,133 shares during the quarter. FMR LLC owned about 15.00% of Dianthus Therapeutics worth $96,776,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Alliancebernstein L.P. raised its position in shares of Dianthus Therapeutics by 13.4% in the 4th quarter. Alliancebernstein L.P. now owns 1,159,776 shares of the company's stock worth $25,283,000 after acquiring an additional 136,633 shares in the last quarter. State Street Corp grew its stake in Dianthus Therapeutics by 101.4% in the third quarter. State Street Corp now owns 821,131 shares of the company's stock worth $22,483,000 after purchasing an additional 413,425 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Dianthus Therapeutics by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 167,021 shares of the company's stock worth $3,641,000 after purchasing an additional 1,092 shares in the last quarter. Wellington Management Group LLP lifted its position in Dianthus Therapeutics by 12.2% during the fourth quarter. Wellington Management Group LLP now owns 60,337 shares of the company's stock valued at $1,315,000 after buying an additional 6,552 shares during the period. Finally, American Century Companies Inc. lifted its position in Dianthus Therapeutics by 3.8% during the fourth quarter. American Century Companies Inc. now owns 43,996 shares of the company's stock valued at $959,000 after buying an additional 1,629 shares during the period. Institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Trading Up 4.9 %

NASDAQ:DNTH traded up $0.95 on Monday, reaching $20.45. 429,594 shares of the stock traded hands, compared to its average volume of 260,904. The company has a market capitalization of $656.98 million, a price-to-earnings ratio of -8.18 and a beta of 1.62. Dianthus Therapeutics, Inc. has a 12 month low of $13.37 and a 12 month high of $32.27. The company's fifty day simple moving average is $20.19 and its 200 day simple moving average is $23.01.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, beating analysts' consensus estimates of ($0.85) by $0.04. The firm had revenue of $1.33 million for the quarter, compared to analysts' expectations of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. Equities analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on DNTH shares. Wedbush reaffirmed an "outperform" rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. HC Wainwright restated a "buy" rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, Guggenheim reaffirmed a "buy" rating and set a $84.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $54.33.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.